topoisomerase inhibition
Recently Published Documents


TOTAL DOCUMENTS

63
(FIVE YEARS 0)

H-INDEX

21
(FIVE YEARS 0)

2020 ◽  
Vol 203 ◽  
pp. 110907 ◽  
Author(s):  
Stephen J. Beebe ◽  
Michael J. Celestine ◽  
Jimmie L. Bullock ◽  
Shayna Sandhaus ◽  
Jessa Faye Arca ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-12
Author(s):  
Abdulrahman I. Almansour ◽  
Raju Suresh Kumar ◽  
Natarajan Arumugam ◽  
Giulia Bianchini ◽  
J. Carlos Menéndez ◽  
...  

A- and D-ring-modified luotonin-inspired heterocycles have been synthesized and were evaluated for their activity against the viability of four cancer cell lines in vitro, namely, MCF7, HCT116, JURKAT, and NCI-H460. The analysis of results indicated that two of the synthesized derivatives displayed good inhibition against the growth of the human colon cancer HCT116 cell line, with potencies lower than but in the same order of magnitude as camptothecin (CPT). These two luotonin analogues also showed an activity similar to that of the highly potent alkaloid CPT as inhibitors of topoisomerase I and also inhibited topoisomerase II. These results show that complete planarity is not a strict requirement for topoisomerase inhibition by luotonin-related compounds, paving the way to the design of analogues with improved solubility.


2019 ◽  
Vol 182 ◽  
pp. 111592 ◽  
Author(s):  
Amélia Galdino Ribeiro ◽  
Sinara Mônica Vitalino de Almeida ◽  
Jamerson Ferreira de Oliveira ◽  
Tulio Ricardo Couto de Lima Souza ◽  
Keriolaine Lima dos Santos ◽  
...  

2019 ◽  
Vol 138 ◽  
pp. 582-589
Author(s):  
Francivaldo Araújo da Silva Filho ◽  
Thais de Freitas Souza ◽  
Amélia Galdino Ribeiro ◽  
Josival Emanuel Ferreira Alves ◽  
Jamerson Ferreira de Oliveira ◽  
...  

2018 ◽  
Vol 26 (22) ◽  
pp. 5911-5921 ◽  
Author(s):  
Rawny Galdino Gouveia ◽  
Amélia Galdino Ribeiro ◽  
Miguel Ângelo Santos Pinheiro Segundo ◽  
Jamerson Ferreira de Oliveira ◽  
Maria do Carmo Alves de Lima ◽  
...  

Oncotarget ◽  
2018 ◽  
Vol 9 (13) ◽  
pp. 11387-11401 ◽  
Author(s):  
Toni Rose Jue ◽  
Emily S. Sena ◽  
Malcolm R. Macleod ◽  
Kerrie L. McDonald ◽  
Theodore C. Hirst

2017 ◽  
Author(s):  
Ayush T. Raman ◽  
Amy E. Pohodich ◽  
Ying-Wooi Wan ◽  
Hari Krishna Yalamanchili ◽  
Bill Lowry ◽  
...  

SUMMARYSeveral recent studies have suggested that genes that are longer than 100 kilobases are more likely to be misregulated in neurological diseases associated with synaptic dysfunction, such as autism and Rett syndrome. These length-dependent transcriptional changes are modest in Mecp2-mutant samples, but, given the low sensitivity of high-throughput transcriptome profiling technology, the statistical significance of these results needs to be re-evaluated. Here, we show that the apparent length-dependent trends previously observed in MeCP2 microarray and RNA-Sequencing datasets, particularly in genes with low fold-changes, disappeared after accounting for baseline variability estimated from randomized control samples. As we found no similar bias with NanoString technology, this long-gene bias seems to be particular to PCR amplification-based platforms. In contrast, authentic long gene effects, such as those caused by topoisomerase inhibition, can be detected even after adjustment for baseline variability. Accurate detection of length-dependent trends requires establishing a baseline from randomized control samples.HIGHLIGHTSLength-dependent gene misregulation is not intrinsic to Mecp2 disruption.Topoisomerase inhibition produces an authentic long gene bias.PCR amplification-based high-throughput datasets are biased toward long genes.


Sign in / Sign up

Export Citation Format

Share Document